Mariner
KROS icon

Mariner’s Keros Therapeutics KROS Stock Holding History

Mariner’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$416K Buy
38,895
+25,069
+181% +$279K ﹤0.01% 2588
2026
Q1 		$153K Sell
13,826
-1,385
-9% -$21.4K ﹤0.01% 3231
2025
Q4 		$310K Sell
15,211
-497
-3% -$8.72K ﹤0.01% 2812
2025
Q3 		$249K Buy
+15,708
New +$232K ﹤0.01% 2982

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Mariner's KROS Position: Q2 2026 in Review

Mariner increased its Keros Therapeutics (KROS) stake by 181% in Q2 2026, buying an estimated $279K and bringing the position to 38,895 shares worth $416K. The position accounts for ﹤0.01% of the portfolio, ranked #2588.

Mariner first reported a position in KROS in Q3 2025 and has held it in 4 quarters since. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Mariner held 38,895 shares of Keros Therapeutics worth $416K as of Q2 2026.
  • Mariner bought 25,069 Keros Therapeutics shares in Q2 2026, an estimated $279K.
  • Keros Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2588 holding.
  • Mariner first reported a position in Keros Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.